T2 BIOSYSTEMS INC (TTOO) Stock Price & Overview

NASDAQ:TTOO • US89853L3024

Current stock price

0.134 USD
-0.06 (-31.07%)
At close:
0.12 USD
-0.01 (-10.45%)
After Hours:

The current stock price of TTOO is 0.134 USD. Today TTOO is down by -31.07%. In the past month the price decreased by -58.13%. In the past year, price decreased by -97.54%.

TTOO Key Statistics

52-Week Range0.11 - 6.8
Current TTOO stock price positioned within its 52-week range.
1-Month Range0.11 - 0.327
Current TTOO stock price positioned within its 1-month range.
Market Cap
3.759M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-7.82
Dividend Yield
N/A

TTOO Stock Performance

Today
-31.07%
1 Week
-41.74%
1 Month
-58.13%
3 Months
-73.04%
Longer-term
6 Months -96.42%
1 Year -97.54%
2 Years -99.78%
3 Years -99.99%
5 Years -100.00%
10 Years -100.00%

TTOO Stock Chart

T2 BIOSYSTEMS INC / TTOO Daily stock chart

TTOO Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to TTOO. When comparing the yearly performance of all stocks, TTOO is a bad performer in the overall market: 99.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TTOO Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to TTOO. TTOO may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TTOO Earnings

Next Earnings DateMay 5, 2025
Last Earnings DateFeb 13, 2025
PeriodQ3 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise -30.50%

TTOO Forecast & Estimates

6 analysts have analysed TTOO and the average price target is 5.1 USD. This implies a price increase of 3705.97% is expected in the next year compared to the current price of 0.134.

For the next year, analysts expect an EPS growth of 83.26% and a revenue growth 51.43% for TTOO


Analysts
Analysts43.33
Price Target5.1 (3705.97%)
EPS Next Y83.26%
Revenue Next Year51.43%

TTOO Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

TTOO Financial Highlights

Over the last trailing twelve months TTOO reported a non-GAAP Earnings per Share(EPS) of -7.82. The EPS increased by 97.25% compared to the year before.


Income Statements
Revenue(TTM)7.68M
Net Income(TTM)-42.95M
Industry RankSector Rank
PM (TTM) N/A
ROA -237.55%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%83.59%
Sales Q2Q%34.85%
EPS 1Y (TTM)97.25%
Revenue 1Y (TTM)-30.16%

TTOO Ownership

Ownership
Inst Owners3.18%
Shares28.05M
Float15.58M
Ins Owners0.1%
Short Float %0.03%
Short Ratio0

About TTOO

Company Profile

TTOO logo image T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Company Info

IPO: 2014-08-07

T2 BIOSYSTEMS INC

101 Hartwell Ave

Lexington MASSACHUSETTS 02421 US

CEO: John Sperzel

Employees: 113

TTOO Company Website

TTOO Investor Relations

Phone: 17814571200

T2 BIOSYSTEMS INC / TTOO FAQ

Can you describe the business of T2 BIOSYSTEMS INC?

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.


Can you provide the latest stock price for T2 BIOSYSTEMS INC?

The current stock price of TTOO is 0.134 USD. The price decreased by -31.07% in the last trading session.


Does T2 BIOSYSTEMS INC pay dividends?

TTOO does not pay a dividend.


How is the ChartMill rating for T2 BIOSYSTEMS INC?

TTOO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the analyst forecast for TTOO stock?

6 analysts have analysed TTOO and the average price target is 5.1 USD. This implies a price increase of 3705.97% is expected in the next year compared to the current price of 0.134.


How is the valuation of T2 BIOSYSTEMS INC (TTOO) based on its PE ratio?

T2 BIOSYSTEMS INC (TTOO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.82).


What is T2 BIOSYSTEMS INC worth?

T2 BIOSYSTEMS INC (TTOO) has a market capitalization of 3.76M USD. This makes TTOO a Nano Cap stock.